Abstract
Genetic Engineering & Biotechnology NewsVol. 40, No. 8 DepartmentsGoing “Cell Free” Can Put a Rush on COVID-19 Antibody TherapiesSwiftScale Biologics has a cell-free protein production platform that can speed development and manufacturing scale-upGail DuttonGail DuttonSearch for more papers by this authorPublished Online:5 Aug 2020https://doi.org/10.1089/gen.40.08.04AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 40Issue 8Aug 2020 Information© 2020 by GEN PublishingTo cite this article:Gail Dutton.Going “Cell Free” Can Put a Rush on COVID-19 Antibody Therapies.Genetic Engineering & Biotechnology News.Aug 2020.12-13.http://doi.org/10.1089/gen.40.08.04Published in Volume: 40 Issue 8: August 5, 2020PDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
